Total Returns (Price + Dividend) 
Healthy Life for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Is Healthy Life overvalued or undervalued?
As of 18 November 2025, the valuation grade for Healthy Life has moved from very attractive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 21.90, an EV to EBITDA of 16.07, and a ROCE of 10.96%. In comparison to its peers, Healthy Life's PE ratio is significantly lower than Hindustan Unilever's 53.39 and Nestle India's 81.48, both of which are categorized as very expensive. Despite this, Healthy Life's current valuation does not justify its price, especially given its recent stock performance, which has seen a drastic decline of 72.29% year-to-date, contrasting sharply with the Sensex's 8.36% gain in the same period....
Read MoreHow has been the historical performance of Healthy Life?
Answer: The historical performance of Healthy Life shows significant growth over the years, particularly in net sales and profitability. Breakdown: Healthy Life's net sales have increased from 33.96 Cr in Mar'22 to 171.87 Cr in Mar'25, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 33.96 Cr in Mar'22 to 171.87 Cr in Mar'25. The company's total expenditure also grew, from 32.78 Cr in Mar'22 to 166.98 Cr in Mar'25, but the operating profit (PBDIT) improved from 1.18 Cr to 4.89 Cr during the same period, indicating enhanced operational efficiency. Profit before tax rose from 1.12 Cr in Mar'22 to 4.35 Cr in Mar'25, while profit after tax increased from 0.83 Cr to 3.26 Cr, showcasing a consistent improvement in profitability. The earnings per share (EPS) fluctuated, reaching 0.83 in Mar'25, down from 1.14 in Mar'24. On the balance sheet, total assets grew...
Read More Announcements 
Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015
14-Nov-2025 | Source : BSESubmission of Unaudited Consolidated and Standalone Financial Results for the half- year ended 30 September 2025 pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015
Submission Of Unaudited Consolidated And Standalone Financial Results For The Half- Year Ended 30 September 2025 Pursuant To Regulation 33 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015
14-Nov-2025 | Source : BSEApproval of Unaudited Financial Results for the period ended 30 September 2025.
Board Meeting Intimation for Regulation 29 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015.
10-Nov-2025 | Source : BSEHealthy Life Agritec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the half-year ended on 30 September 2025 and any other matter with the permission of the Chai.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Healthy Life Agritec Ltd has announced 1:1 rights issue, ex-date: 26 Sep 25
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Nov 2025
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 1 FIIs (0.4%)
Cronosglobal Investments & Holdings Private Limited (18.17%)
Santa Ghosh (2.9%)
60.49%
Quarterly Results Snapshot (Standalone) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 7.47% vs 13.20% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 4.35% vs 17.95% in Mar 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 8.50% vs -4.67% in Mar 2025
Growth in half year ended Sep 2025 is -22.49% vs 78.63% in Mar 2025
Nine Monthly Results Snapshot (Consolidated) - Jun'25
YoY Growth in nine months ended Jun 2025 is 2.31% vs 57.38% in Jun 2025
YoY Growth in nine months ended Jun 2025 is 22.50% vs 58.73% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 29.27% vs 23.31% in Mar 2024
YoY Growth in year ended Mar 2025 is 29.88% vs 66.23% in Mar 2024






